Louise Kooij - Mar 26, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Accounting Officer
Signature
/s/ Louise Kooij
Stock symbol
NAMS
Transactions as of
Mar 26, 2025
Transactions value $
$0
Form type
4
Date filed
3/28/2025, 05:29 PM
Previous filing
Mar 5, 2025
Next filing
Aug 27, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Options Exercise $0 +8.27K +55.13% $0.00 23.3K Mar 26, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Restricted Stock Unit Award +8.27K 8.27K Mar 26, 2025 Ordinary Shares 8.27K Direct F1, F2, F3
transaction NAMS Restricted Stock Unit Options Exercise -8.27K -100% 0 Mar 26, 2025 Ordinary Shares 8.27K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.
F2 Upon grant, all of the RSUs were fully-vested.
F3 The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.